Issues: Vax Specific

Anthrax

Hepatitis B

Hib

Influenza

Lyme Disease
Meningococcal

MMR    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

2008 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

MENINGOCOCCAL VACCINE

  • ACIP simplifies Meningitis vaccine for all adolescents 11-18 years of age. link July 12, 2007

  • Update on Guillain Barre Syndrome following meningococcal conjugate vaccine (Menactra):  No change in recommendations for use of the vaccine
    The FDA and CDC have updated their information on Guillain Barre Syndrom (GBS) after meningococcal conjugate vaccine [link to MMWR].  GBS is a neurological disorder associated with a progressive paralysis over several days to weeks.  Most people with GBS recover over a period of many weeks of months.  The evidence generated by CDC and FDA suggests that there could be an increased risk of GBS of about one in one million following Menactrra in adolescents, but additional studies are needed to clearly answer this question.
    Since the known risk of severe complications from meningococcal infections is high in this age group, the CDC has not altered the recommendations for routine use for adolescents, college freshmen living in dorms and others at high risk for the disease.
    CDC has provided detailed information (11-01-06)

  • Guillain-Barré Syndrome Among Recipients of Menactra® Meningococcal Conjugate Vaccine --- United States, June--July 2005.  MMWR 2005;54(Dispatch);1-3. - Descriptions and details about the 5 cases of GBS after receipt of meningococcal vaccine.  (10- 2005)

  • FDA/CDC issue an alert on meningococcal vaccine following 5 reported cases of Guillain Barre Syndrom after receipt of Menactra.  (10-2005)

This page was last updated on January 23, 2008

© 2006 Institute for Vaccine Safety